Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison R Hill

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Scientific Reports|July 7, 2019
Engineering multi-layered tissue constructs using acoustic levitationAngela Tait, Peter Glynne-Jones, Alison R Hill, et al.
The Journal of Clinical Investigation|January 17, 2023
Distinct early cellular kinetics in participants protected against colonization upon Bordetella pertussis challengeAnnieck M Diks, Hans de Graaf, Cristina Teodosio, et al.
NPJ Vaccines|April 18, 2026
BPZE1 vaccination induces IL-17<sup>+</sup> and IL-22<sup>+</sup> CD4<sup>+</sup> T cells associated with nasal mucosal secretory IgA responses in humans: effects on virulent Bordetella pertussis colonisationAlison R Hill, Diane F Gbesemete, Tyween Coutinho, et al.
Tissue Barriers|September 2, 2016
IL-1α mediates cellular cross-talk in the airway epithelial mesenchymal trophic unitAlison R Hill, Jessica E Donaldson, Cornelia Blume, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 29, 2019
Controlled Human Infection With Bordetella pertussis Induces Asymptomatic, Immunizing ColonizationHans de Graaf, Muktar Ibrahim, Alison R Hill, et al.
The Lancet. Microbe|December 3, 2022
Effect of colonisation with Neisseria lactamica on cross-reactive anti-meningococcal B-cell responses: a randomised, controlled, human infection trialAdam P Dale, Anastasia A Theodosiou, Diane F Gbesemete, et al.
The Lancet. Microbe|December 4, 2025
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussisDiane Gbesemete, Maheshi N Ramasamy, Muktar Ibrahim, et al.
The Lancet. Microbe|March 26, 2026
Safety, colonisation kinetics, transmissibility, and immune correlates of protection in healthy adults inoculated with Bordetella pertussis in England: a single-centre, open-label, phase 1, controlled human infection studyHans de Graaf, Diane F Gbesemete, Alison R Hill, et al.
Science Translational Medicine|July 8, 2021
A recombinant commensal bacteria elicits heterologous antigen-specific immune responses during pharyngeal carriageJay R Laver, Diane Gbesemete, Adam P Dale, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Scientific Reports|July 7, 2019
Engineering multi-layered tissue constructs using acoustic levitationAngela Tait, Peter Glynne-Jones, Alison R Hill, et al.
The Journal of Clinical Investigation|January 17, 2023
Distinct early cellular kinetics in participants protected against colonization upon Bordetella pertussis challengeAnnieck M Diks, Hans de Graaf, Cristina Teodosio, et al.
NPJ Vaccines|April 18, 2026
BPZE1 vaccination induces IL-17<sup>+</sup> and IL-22<sup>+</sup> CD4<sup>+</sup> T cells associated with nasal mucosal secretory IgA responses in humans: effects on virulent Bordetella pertussis colonisationAlison R Hill, Diane F Gbesemete, Tyween Coutinho, et al.
Tissue Barriers|September 2, 2016
IL-1α mediates cellular cross-talk in the airway epithelial mesenchymal trophic unitAlison R Hill, Jessica E Donaldson, Cornelia Blume, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 29, 2019
Controlled Human Infection With Bordetella pertussis Induces Asymptomatic, Immunizing ColonizationHans de Graaf, Muktar Ibrahim, Alison R Hill, et al.
The Lancet. Microbe|December 3, 2022
Effect of colonisation with Neisseria lactamica on cross-reactive anti-meningococcal B-cell responses: a randomised, controlled, human infection trialAdam P Dale, Anastasia A Theodosiou, Diane F Gbesemete, et al.
The Lancet. Microbe|December 4, 2025
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussisDiane Gbesemete, Maheshi N Ramasamy, Muktar Ibrahim, et al.
The Lancet. Microbe|March 26, 2026
Safety, colonisation kinetics, transmissibility, and immune correlates of protection in healthy adults inoculated with Bordetella pertussis in England: a single-centre, open-label, phase 1, controlled human infection studyHans de Graaf, Diane F Gbesemete, Alison R Hill, et al.
Science Translational Medicine|July 8, 2021
A recombinant commensal bacteria elicits heterologous antigen-specific immune responses during pharyngeal carriageJay R Laver, Diane Gbesemete, Adam P Dale, et al.
Pageof 1